ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 021,66
-1,13%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Adverum Biotechnologies Inc (ADVM)

  7. Adverum Biotechnologies Inc (ADVM) Actualités

ADVM Adverum Biotechnologies Inc

9,19
-0,20 (-2,13%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Adverum Biotechnologies Inc ADVM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,20 -2,13% 9,19 22:36:37
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
9,60 9,11 10,10 9,19 9,39
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202422:05GLOBEAdverum Biotechnologies to Present LUNA 26-week Phase 2..
18/3/202421:05GLOBEAdverum Biotechnologies Reports Fourth Quarter and Full Year..
04/3/202422:40EDGAR2Form S-3 - Registration statement under Securities Act of..
28/2/202422:05GLOBEAdverum Biotechnologies to Participate in the TD Cowen 44th..
22/2/202421:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202421:39EDGAR2Form D - Notice of Exempt Offering of Securities
15/2/202422:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
15/2/202402:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202414:00GLOBEAdverum Biotechnologies to Participate in the Oppenheimer..
09/2/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202417:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202414:45EDGAR2Form 8-K - Current report
08/2/202413:00GLOBEAdverum Biotechnologies Announces Positive Preliminary..
06/2/202422:47EDGAR2Form 8-K - Current report
05/2/202423:03EDGAR2Form 8-K - Current report
05/2/202413:45GLOBEAdverum Biotechnologies Announces $127.5 Million Private..
01/2/202423:30GLOBEAdverum Biotechnologies will Host Webcast to Review LUNA..
29/1/202414:00GLOBEAdverum Biotechnologies Appoints Romuald Corbau, Ph.D. as..
08/12/202322:11EDGAR2Form 8-K - Current report
07/12/202322:05GLOBEAdverum Biotechnologies to Present LUNA Preliminary Efficacy..
04/12/202322:09EDGAR2Form 8-K/A - Current report: [Amend]
28/11/202322:05GLOBEAdverum Biotechnologies to Participate in the Evercore ISI..
09/11/202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:07EDGAR2Form 8-K - Current report
09/11/202322:05GLOBEAdverum Biotechnologies Reports Third Quarter 2023 Financial..
07/11/202301:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202301:52EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/11/202322:10EDGAR2Form 8-K - Current report
06/11/202314:00GLOBEAdverum Biotechnologies Appoints C. David Nicholson, Ph.D...
04/11/202322:54GLOBEAdverum Biotechnologies Announces 3-Year Efficacy and Safety..
26/9/202322:05GLOBEAdverum Biotechnologies Announces Positive Aflibercept..
21/9/202322:05GLOBEAdverum Biotechnologies to Participate in Upcoming Investor..
19/9/202300:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:05GLOBEAdverum Biotechnologies to Participate in the H.C...
21/8/202322:05GLOBEAdverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as..
14/8/202314:00GLOBEAdverum Biotechnologies to Participate in the H.C...
10/8/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:09EDGAR2Form 8-K - Current report
10/8/202322:05GLOBEAdverum Biotechnologies Completes Enrollment of Phase 2 LUNA..
04/8/202322:18EDGAR2Form 8-K - Current report
24/7/202322:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/6/202314:00GLOBEAdverum Biotechnologies Grants License to Ray Therapeutics..
02/6/202314:00GLOBEAdverum Biotechnologies to Participate in the Jefferies..
25/5/202312:30GLOBEAdverum Biotechnologies Announces New Executive Leadership..
18/5/202315:00GLOBEAdverum Biotechnologies Presents Nonclinical Data in Support..
11/5/202322:05GLOBEAdverum Biotechnologies Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
ADVM
Adverum Biotechnologies
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés